Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. reports clinical-stage biopharmaceutical developments tied to novel small-molecule therapeutics derived from its boron chemistry platform. Company updates center on infectious-disease programs such as Chagas disease, NTM lung disease caused by Mycobacterium abscessus and melioidosis, along with oncology, hematologic-disease and other research programs.
Recurring ANTX news includes clinical and regulatory updates for candidates such as epetraborole and AN2-502998, investigator-initiated trial activity, operating and financial results, material agreements, governance matters and investor conference participation.
AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of its initial public offering (IPO) of 4,600,000 shares at $15.00 each, aiming to raise $69.0 million. The IPO is set to begin trading on Nasdaq under the symbol ANTX on March 25, 2022, and is expected to close on March 29, 2022. The underwriters also hold a 30-day option to purchase an additional 690,000 shares. The funds raised are intended to support AN2’s development of epetraborole, an oral treatment for rare infectious diseases.